Doctors are implanting lab-grown stem cells into Parkinson's patients' brains in a groundbreaking clinical trial to restore dopamine production. The FDA has granted the Phase 1 REPLACE trial fast-track designation, testing iPSC-derived dopamine-producing cells in 12 patients with moderate to severe Parkinson's. Researchers will monitor participants for up to five years to assess motor function restoration and potential side effects.
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
Moderna shares declined nearly 6% amid extreme options market volatility and a new patent infringement lawsuit from BioNTech. The company faces significant financial challenges with negative earnings and declining revenue growth, while valuation metrics suggest potential overvaluation. Technical indicators point to bearish short-term momentum as the stock approaches key support levels.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The phase III TOP study shows osimertinib plus chemotherapy more than doubles progression-free survival to 34 months versus 15.6 months with osimertinib alone in EGFR/TP53 mutant NSCLC. The combination achieved an 82.9% response rate and represents a new strategy for this high-risk subgroup. Research continues into resistance mechanisms, including cancer-associated fibroblasts' role in promoting osimertinib resistance.
Prime Minister Mark Carney's Major Projects Office, created to fast-track nation-building infrastructure projects, has not accepted any projects six months after legislation passed. The program aims to reduce federal permitting from 7-10 years to two years but faces limitations with local review boards and Indigenous consent requirements.
Moderna will pay $2.25 billion to settle patent disputes with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle technology used in its COVID-19 vaccine. The settlement removes uncertainty for Moderna's vaccine pipeline and sent the stock surging over 11%. The company expects to end 2026 with $4.5-$5 billion in cash and return to revenue growth by year-end.
Two Mexican nationals have been extradited to face federal drug trafficking charges in New Mexico. Daniel Alfred Blanco-Joo faces five counts including fentanyl distribution and money laundering, while David Eliezer Seas-Centeno faces conspiracy to distribute fentanyl. Both defendants face minimum 10-year prison sentences if convicted.
Novartis AG shows mixed short-term share performance but stronger long-term returns, with institutional investors increasing stakes. Analysts debate whether the stock is overvalued or undervalued, with an average "Hold" rating and $119.75 target price. The pharmaceutical company reported quarterly earnings of $2.03 per share, beating estimates, with revenue up 1.4% year-over-year.
Autolus Therapeutics reported $74.3 million in 2025 revenue during its first commercial year, while facing a -265% gross margin. The company aims to achieve positive margins by 2026 through scaling production and expanding into autoimmune diseases with promising early lupus trial results. The broader CAR-T therapy market is projected to reach $9.85 billion in the US by 2033.
Sacituzumab tirumotecan demonstrated a median overall survival of 20.0 months versus 13.5 months with docetaxel in pretreated EGFR-mutated NSCLC patients. The phase 2 OptiTROP-Lung03 study showed a hazard ratio of 0.63 for overall survival benefit with the TROP2-directed antibody-drug conjugate.
The FDA will now allow drug approval based on a single pivotal trial instead of two, a policy change confirmed in a New England Journal of Medicine paper. The new guidance maintains requirements for confirmatory evidence and focuses on trial design quality, aiming to reduce development costs and speed drugs to market. FDA officials argue this approach may actually improve standards by concentrating scrutiny on a single well-designed study.
Class action lawsuits allege false statements about clinical trial results and regulatory prospects at Atara Biotherapeutics, Ultragenyx, Mereo BioPharma, and Vistagen Therapeutics. The complaints cite failed Phase 3 studies for setrusumab in Osteogenesis Imperfecta and fasedienol for social anxiety disorder, along with manufacturing issues affecting Atara's tabelecleucel application. Investors have deadlines ranging from April to May 2026 to seek lead plaintiff status.
A Phase 3 trial shows administering immunochemotherapy before 3:00 PM improves survival outcomes in advanced NSCLC. Early treatment resulted in 11.3 months progression-free survival versus 5.7 months for late treatment, and 28.0 months overall survival versus 16.8 months. The findings suggest treatment timing is a modifiable factor that can enhance efficacy without additional cost.
DEA and New York authorities seized over 8,800 counterfeit fentanyl pills and 891 grams of cocaine in Brooklyn, arresting one suspect. In a separate operation, agents recovered 20 pounds of methamphetamine and $50,000 in cash. The busts are part of efforts to disrupt synthetic drug shipments into New York City.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
